New Skin Toxicities for New Anticancer Therapies

Giulia Ganzetti, MD, Anna Campanati and Annamaria Offidani (Editors)
Dermatology Unit, Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona, Italy

Series: Dermatology – Laboratory and Clinical Research
BISAC: MED017000

Clear

$130.00

Volume 10

Issue 1

Volume 2

Volume 3

Special issue: Resilience in breaking the cycle of children’s environmental health disparities
Edited by I Leslie Rubin, Robert J Geller, Abby Mutic, Benjamin A Gitterman, Nathan Mutic, Wayne Garfinkel, Claire D Coles, Kurt Martinuzzi, and Joav Merrick

eBook

Digitally watermarked, DRM-free.
Immediate eBook download after purchase.

Product price
Additional options total:
Order total:

Quantity:

Browse Wishlist
Browse Wishlist

Details

Targeted cancer therapies have revolutionized the therapeutic management of many neoplasms, modifying patients’ prognosis and overall survival. These drugs block the cancer’s growth and spread by interfering with specific molecules which play a crucial role in the proliferation, differentiation and survival of cancer cells. Targeted therapies act selectively on specific molecular targets related to cancers, whereas most of the conventional chemotherapies act on all rapidly dividing normal and neoplastic cells.

Moreover, targeted therapies are often cytostatic and non-cytotoxic as standard chemotherapies. Taken together, these aspects appear important in reducing systemic toxicity and ensuring an improved safety profile. The inhibition of epidermal growth factor receptor (EGFR), vascular growth factor (VEGF) and BRAF represents major achievements in research and development of solid tumors’ epithelial therapy.

This class of biologics is currently widely used in the treatment of metastatic and unresponsive neoplasms of the colon, pancreas, lung, (NSCLC), breast, head and neck and melanoma. This book aims to emphasize skin toxicity associated with EGFR-, VEGF- and BRAF- inhibitors, focusing particularly on their clinical presentation, histopathological findings, and specific therapeutic options. (Imprint: Nova Biomedical)

Preface

New Targeted Anticancer Therapies: Classification and Mechanism of Action
(M Caramanti, F Morgese, A Savini, R Berardi, Medical Oncology Clinic, Polytechnic Marche University)

Skin Toxicities from EGFR Inhibitors
(G Ganzetti, A Offidani, Dermatology Unit, Department of Clinical and Molecular Sciences, Polytechnic Marche University)

Skin Toxicities from VEGF Inhibitors
(E Molinelli, A Offidani, Dermatology Unit, Department of Clinical and Molecular Sciences, Polytechnic Marche University)

Skin Toxicity from BRAF Inhibitors
(A Campanati, A Offidani, Dermatology Unit, Department of Clinical and Molecular Sciences, Polytechnic Marche University)

Addendum: Classification of EGFR-Related Skin Rash
(K Giuliodori, A Offidani, Dermatology Unit, Department of Clinical and Molecular Sciences, Polytechnic Marche University)

Index

You have not viewed any product yet.